Allergy Therapeutics (AGY) AI Stock Analysis

• Market Cap: £381.32M
• Dividend Yield: N/A
• Average Volume (3M): 393.22K
• Price to Earnings (P/E): ―
• Beta (1Y): 0.16
• Revenue Growth: 4.50%
• EPS Growth: 74.32%
• Country: UK
• Employees: 612
• Sector: Healthcare
• Sector Strength: 37
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): >-0.01
• Shares Outstanding: 4,766,440,000
• 10 Day Avg. Volume: 404,343
• 30 Day Avg. Volume: 393,223
• PEG Ratio: -0.38
• Price to Book (P/B): -53.33
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -11.72
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: £7.50
• Price Target Upside: -6.25% Downside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 53 Neutral
• Price Target: 8.00p ▲(0.00%Upside)

Allergy Therapeutics has significant financial challenges, which are the most impactful factor on its stock score. However, technical analysis shows some positive momentum, and promising corporate events suggest potential future growth, partially offsetting financial weaknesses. Valuation concerns remain due to negative earnings.

Allergy Therapeutics Business Overview & Revenue Model

Company Description

Allergy Therapeutics plc, a biotechnology company, engages in the research and development of allergy treatments. The company sells injectable and sublingual allergen-specific immunotherapies; and offers prescription for the treatment of pollen-related allergies particularly to grasses, weeds, and trees, as well as diagnostics. Its products include Pollinex Quattro, Oralvac, Venomil, ImmunoBON, Synbiotics, Acarovac Plus, Penicillin diagnostics, Pollinex, and VLP Peanut. The company also develops allergy vaccines for trees, grass, house dust mite, and pets with fur/hair, as well as peanut allergy vaccines. It operates in Central Europe, Southern Europe, the United Kingdom, and internationally. Allergy Therapeutics plc was incorporated in 2004 and is headquartered in Worthing, the United Kingdom.

How the Company Makes Money

Allergy Therapeutics generates revenue primarily through the sale of its allergy immunotherapy products. The company's key revenue streams include direct sales of its proprietary allergy vaccines to healthcare providers, clinics, and hospitals. Additionally, the company may engage in partnerships and licensing agreements with other pharmaceutical companies to expand the reach and distribution of its products. Significant factors contributing to its earnings include ongoing research and development activities aimed at enhancing product efficacy and the expansion of its product portfolio to address a broader range of allergic conditions.

Allergy Therapeutics Financial Statement Overview

Summary

Allergy Therapeutics is facing significant financial difficulties, with declining revenues, negative net profit margins, and high leverage indicated by the balance sheet. The negative operating and free cash flows further highlight the company's financial strain and liquidity issues.

Income Statement

The company has faced declining revenue over the past two years, with a noticeable revenue decrease in the most recent year. Gross profit margin decreased from previous years, and the net profit margin is negative, indicating losses. EBIT and EBITDA margins are also negative, suggesting operational challenges and reduced profitability.

Balance Sheet

The balance sheet shows a high debt-to-equity ratio, indicating significant leverage. Stockholders' equity has drastically decreased, impacting the equity ratio negatively. The return on equity is negative due to consistent net losses, highlighting financial instability.

Cash Flow

Operating cash flow is negative and declining, highlighting cash management issues. The free cash flow remains negative, and the free cash flow to net income ratio is unfavorable. Despite a positive financing cash flow, overall cash flow indicators reflect financial strain.

Breakdown	Jun 2024	Jun 2023	Jun 2022	Jun 2021	Jun 2020
Income Statement
Total Revenue	55.20M	59.59M	72.77M	84.33M	78.20M
Gross Profit	29.74M	32.69M	48.95M	61.80M	57.51M
EBITDA	-30.74M	-36.24M	-8.69M	7.61M	11.69M
Net Income	-40.22M	-43.07M	-13.78M	2.89M	7.06M
Balance Sheet
Total Assets	64.83M	66.77M	72.95M	88.09M	86.22M
Cash, Cash Equivalents and Short-Term Investments	12.91M	14.85M	20.52M	40.27M	36.96M
Total Debt	30.99M	35.99M	10.53M	11.17M	12.18M
Total Liabilities	61.12M	64.70M	35.18M	39.55M	42.44M
Stockholders Equity	3.71M	2.07M	37.77M	48.53M	43.78M
Cash Flow
Free Cash Flow	-35.54M	-35.59M	-17.17M	5.95M	9.73M
Operating Cash Flow	-32.14M	-30.92M	-14.11M	8.52M	12.28M
Investing Cash Flow	-1.20M	-4.67M	-3.06M	-2.76M	-2.77M
Financing Cash Flow	31.43M	29.91M	-2.64M	-2.03M	-110.00K

Allergy Therapeutics Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 8.00
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For GB:AGY, the sentiment is Positive. The current price of 8 is above the 20-day moving average (MA) of 7.98, above the 50-day MA of 7.46, and above the 200-day MA of 6.51, indicating a bullish trend. The MACD of 0.20 indicates Positive momentum. The RSI at 54.33 is Neutral, neither overbought nor oversold. The STOCH value of 54.17 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for GB:AGY.

Allergy Therapeutics Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
HIK	75 Outperform	£4.38B	15.64	15.79%	0.15%	5.83%	83.35%
AGY	53 Neutral	£381.32M	―	-369.20%	―	4.50%	74.32%
Sector *	50 Neutral	AU$2.61B	3.12	-57.47%	2.45%	36.73%	13.67%

Allergy Therapeutics Corporate Events

Allergy Therapeutics Maintains Stable Performance Amid Strategic Growth Initiatives

Allergy Therapeutics reported stable financial performance for the year ending June 2025, with revenues slightly declining to £55.0 million from £55.2 million in 2024. The company is strategically positioned for growth, leveraging its registered product portfolio amid changing German regulations and advancing key R&D programs, including the Grass MATA MPL and VLP Peanut trials. Despite the need for additional funding from August, major shareholders remain supportive, ensuring continued progress in both commercial and innovative pipeline areas.

Allergy Therapeutics Issues Over 250 Million Warrants Amid Financial Strategy

Allergy Therapeutics has issued 250,674,403 warrants to subscribe for new ordinary shares as part of its financial arrangements with SkyGem Acquisition Limited and Southern Fox Investments Limited. This issuance is linked to a £50 million loan facility, under which the company drew £10 million, necessitating the issuance of warrants. Additionally, 674,403 warrants were issued to Hayfin Healthcare Opportunities LuxCo S.a.r.l. due to anti-dilution rights. This move is part of the company’s strategy to manage its financial obligations and could impact its market positioning by potentially increasing its share capital.

Allergy Therapeutics Unveils Promising Research at EAACI 2025

Allergy Therapeutics announced key scientific findings at the EAACI 2025 Congress, highlighting advancements in their research portfolio. The company presented promising results from its peanut allergy vaccine candidate and Grass MATA MPL immunotherapy, both showing potential to transform patient care by improving quality of life and inducing beneficial immune responses. These developments underscore the company’s commitment to expanding its VLP platform in food allergies and enhancing treatment options for allergic diseases.

Allergy Therapeutics and EAACI Honor Early Career Researcher

Allergy Therapeutics, in collaboration with the European Academy of Allergy and Clinical Immunology (EAACI), announced Dr. Janice Layhadi as the winner of the EAACI Early Career Research Award. This award supports young researchers in allergen immunotherapy, providing essential funding to advance their research. Dr. Layhadi’s work focuses on biomarker discovery in allergen immunotherapy, which is expected to enhance understanding and treatment of allergic conditions, ultimately improving patient outcomes.